52 Works

Additional file 1 of Oral health-related quality of life in rheumatoid arthritis: a comparative analysis

Amirhossein Parsaei, Aida Mehdipour, Hamidreza Ghadimi, Ashkan Mohammadi Kooshki, Parisa Shajari, Maryam Masoumi, Pouya Torabi, Hossein Azizi, Behnam Amini, Hanie Karimi, Hojat Dehghanbanadaki, Mohammad Aghaali & Soroush Moradi
Additional file 1. Table 1. Temporomandibular joint disorder questionnaire.

Additional file 1 of A systematic review of strategies used for controlling consumer moral hazard in health systems

Zohreh Koohi Rostamkalaee, Mehdi Jafari & Hasan Abolghasem Gorji
Supplementary Material 1

Additional file 3 of A systematic review of strategies used for controlling consumer moral hazard in health systems

Zohreh Koohi Rostamkalaee, Mehdi Jafari & Hasan Abolghasem Gorji
Supplementary Material 3

Additional file 1 of Psychometric properties of public trust in Covid-19 control and prevention policies questionnaire

Riaz Alaei Kalajahi, Mohammad Saadati, Saber Azami Aghdash, Ramin Rezapour, Mehdi Nouri, Naser Derakhshani & Koustuv Dalal
Supplementary Material 1

Additional file 1 of Association between gout and the development of Parkinson’s disease: a systematic review and meta-analysis

Asra Fazlollahi, Mahdi Zahmatyar, Hossein Alizadeh, Maryam Noori, Nasrin Jafari, Seyed Aria Nejadghaderi, Mark J. M. Sullman, Koroush Gharagozli, Ali-Asghar Kolahi & Saeid Safiri
Additional file 1: Supplementary Table 1. Search strategies for PubMed, Scopus, Web of Science, and Google scholar. Supplementary Table 2. Comorbid conditions of individuals who participated in the studies included in the meta-analysis. Supplementary Table 3. Risk of bias assessment for the included cohort studies. Supplementary Table4. Risk of bias assessments for the included case-control studies.

Additional file 2 of The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019

Hamidreza Feizi, Mahasti Alizadeh, Seyed Aria Nejadghaderi, Maryam Noori, Mark J. M. Sullman, Javad Ahmadian Heris, Ali-Asghar Kolahi, Gary S. Collins & Saeid Safiri
Additional file 2: Table S2. Prevalence of chronic obstructive pulmonary disease in 1990 and 2019 for both sexes and percentage change in age-standardised rates (ASRs) per 100,000 in the Middle East and North Africa region (generated from data available from http://ghdx.healthdata.org/gbd-results-tool ).

Additional file 2 of The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019

Hamidreza Feizi, Mahasti Alizadeh, Seyed Aria Nejadghaderi, Maryam Noori, Mark J. M. Sullman, Javad Ahmadian Heris, Ali-Asghar Kolahi, Gary S. Collins & Saeid Safiri
Additional file 2: Table S2. Prevalence of chronic obstructive pulmonary disease in 1990 and 2019 for both sexes and percentage change in age-standardised rates (ASRs) per 100,000 in the Middle East and North Africa region (generated from data available from http://ghdx.healthdata.org/gbd-results-tool ).

Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis

Maryam Noori, Farimah Fayyaz & Nima Rezaei
We evaluate the efficacy and safety of Elotuzumab, an immunostimulatory monoclonal antibody, in combination with concomitant treatment regimens for multiple myeloma (MM) patients. PubMed, Scopus, Web of Science, and EMBASE databases were searched systematically up to 2 August 2022. Five randomized control trials with a total of 1,763 participants were included. Elotuzumab combination therapy improved PFS and OS by 14% (hazard ratio [HR] 0.86) and 20% (HR 0.80), respectively, relative to the non-Elotuzumab regimen. Adding...

Additional file 1 of Structural analysis of PpSP15 and PsSP9 sand fly salivary proteins designed with a self-cleavable linker as a live vaccine candidate against cutaneous leishmaniasis

Mahya Sadat Lajevardi, Tahereh Taheri, Elham Gholami, Negar Seyed & Sima Rafati
Additional file 1: Table S1. Nucleic acid and protein sequences of all components needed for construct design. Figure S1. Complete sequence of Utr1 and Utr2 of LEXSYcon2 vector. Trans-splicing sites used in mRNA synthesis are highlighted in blue (longest polypyrimidine tract), red (splice acceptor site), and purple (polyA site). Utr1 and Utr2 sequences are obtained from the LEXSYcon2 Expression Kit’s manual (Jena Bioscience). Figure S2. Optimal and centroid secondary structure analysis by RNAfold for all...

Additional file 1 of Structural analysis of PpSP15 and PsSP9 sand fly salivary proteins designed with a self-cleavable linker as a live vaccine candidate against cutaneous leishmaniasis

Mahya Sadat Lajevardi, Tahereh Taheri, Elham Gholami, Negar Seyed & Sima Rafati
Additional file 1: Table S1. Nucleic acid and protein sequences of all components needed for construct design. Figure S1. Complete sequence of Utr1 and Utr2 of LEXSYcon2 vector. Trans-splicing sites used in mRNA synthesis are highlighted in blue (longest polypyrimidine tract), red (splice acceptor site), and purple (polyA site). Utr1 and Utr2 sequences are obtained from the LEXSYcon2 Expression Kit’s manual (Jena Bioscience). Figure S2. Optimal and centroid secondary structure analysis by RNAfold for all...

Additional file 1 of Design, synthesis, in vitro, and in silico biological evaluations of coumarin-indole hybrids as new anti-α-glucosidase agents

Davood Rezapour Niri, Mohammad Hosein Sayahi, Somayeh Behrouz, Ali Moazzam, Somayeh Mojtabavi, Mohammad Ali Faramarzi, Bagher Larijani, Hossein Rastegar, Maryam Mohammadi-Khanaposhtani & Mohammad Mahdavi
Additional file 1. Images of 1H NMR and 13C NMR of the new synthesized compounds 5a-m and IC50 graphs of these compounds are available in the Supporting Information.

Additional file 1 of Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity

Nasrin Nassiri Koopaei, Mehrasa Shademani, Nasrin Shirzad Yazdi, Raheleh Tahmasvand, Mina Dehbid, Mansur Nassiri Koopaei, Homa Azizian, Zahra Mousavi, Ali Almasirad & Mona Salimi
Additional file 1. Spectral data including FT-IR,1HNMR, 13CNMR and Mass for compounds (4a–4i).

Phenolic content and antioxidant activity of different Iranian populations of Anabasis aphylla L.

Mohabat Nadaf, Majid Halimi Khalil Abad, Ali Gholami, Mohammad Ehsan Taghavizadeh Yazdi, Marcello Iriti & Javad Mottaghipisheh
The Anabasis aphylla L. aerial parts was harvested from five different populations located in Golestan National Park, Iran. The phenolic content and antioxidant potencies of the ethanolic extracts were measured using the Folin–Ciocalteu and 2,2-diphenyl-1-picrylhydrazyl (DPPH) methods, respectively. Moreover, the effects of two factors soil electrical conductivity and soil acidity on phenolic content and antioxidant properties of the extracts were evaluated. Consequently, no significant difference between different populations of Anabasis aphylla L. in terms of...

Additional file 1 of The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019

Hamidreza Feizi, Mahasti Alizadeh, Seyed Aria Nejadghaderi, Maryam Noori, Mark J. M. Sullman, Javad Ahmadian Heris, Ali-Asghar Kolahi, Gary S. Collins & Saeid Safiri
Additional file 1: Table S1. Health states for chronic obstructive pulmonary disease and the associated disability weights from the Global Burden of Disease 2019 Study.

Additional file 3 of The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019

Hamidreza Feizi, Mahasti Alizadeh, Seyed Aria Nejadghaderi, Maryam Noori, Mark J. M. Sullman, Javad Ahmadian Heris, Ali-Asghar Kolahi, Gary S. Collins & Saeid Safiri
Additional file 3: Table S3. Deaths of chronic obstructive pulmonary disease in 1990 and 2019 for both sexes and percentage change in age-standardised rates (ASRs) per 100,000 in the Middle East and North Africa region (generated from data available from http://ghdx.healthdata.org/gbd-results-tool ).

Additional file 4 of The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019

Hamidreza Feizi, Mahasti Alizadeh, Seyed Aria Nejadghaderi, Maryam Noori, Mark J. M. Sullman, Javad Ahmadian Heris, Ali-Asghar Kolahi, Gary S. Collins & Saeid Safiri
Additional file 4: Table S4. DALYs due to chronic obstructive pulmonary disease in 1990 and 2019 for both sexes and percentage change in age-standardised rates (ASRs) per 100,000 in the Middle East and North Africa region (generated from data available from http://ghdx.healthdata.org/gbd-results-tool ).

Additional file 6 of The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019

Hamidreza Feizi, Mahasti Alizadeh, Seyed Aria Nejadghaderi, Maryam Noori, Mark J. M. Sullman, Javad Ahmadian Heris, Ali-Asghar Kolahi, Gary S. Collins & Saeid Safiri
Additional file 6: Figure S2. The percentage change in the age-standardised death of chronic obstructive pulmonary disease in the Middle East and North Africa region from 1990 to 2019, by sex and country (generated from data available from http://ghdx.healthdata.org/gbd-results-tool ).

Additional file 1 of Home care nurses’ perception of the challenges they faced during the COVID-19 pandemic: a qualitative study

Tahereh Najafi Ghezeljeh, Sahar Keyvanloo Shahrestanaki, Zahra Amrollah Majdabadi kohne & Ehsan Fakhari
Additional file 1: Supplement Table1. Saturation grid.

Additional file 1 of Synthesis and bioactivities evaluation of quinazolin-4(3H)-one derivatives as α-glucosidase inhibitors

Mahshid Moheb, Aida Iraji, Navid Dastyafteh, Minoo Khalili Ghomi, Milad Noori, Somayeh Mojtabavi, Mohammad Ali Faramarzi, Fatemeh Rasekh, Bagher Larijani, Kamiar Zomorodian, Seyed Esmaeil Sadat-Ebrahimi & Mohammad Mahdavi
Additional file 1: Figure S1. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-phenylacetamide (7a). Figure S2. N-(2-fluorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7b). Figure S3. N-(4-fluorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7c). Figure S4. N-(2-chlorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7d). Figure S5. N-(3-chlorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7e). Figure S6. N-(4-chlorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7f). Figure S7. N-(4-bromophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7g). Figure S8. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(o-tolyl)acetamide (7 h). Figure S9. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(p-tolyl)acetamide (7i). Figure S10. N-(2,6-dimethylphenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7j). Figure S11. N-(4-ethylphenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7k). Figure S12. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(4-methoxyphenyl)acetamide (7 l). Figure S13. N-(4-hydroxyphenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7m). Figure S14. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(4-nitrophenyl)acetamide (7n). Figure S15. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(naphthalen-2-yl)acetamide (7o). Figure S16. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(4-methylbenzyl)acetamide (7p). Figure S17. N-(4-fluorobenzyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7q). Figure S18....

Additional file 1 of A systematic review of strategies used for controlling consumer moral hazard in health systems

Zohreh Koohi Rostamkalaee, Mehdi Jafari & Hasan Abolghasem Gorji
Supplementary Material 1

Additional file 3 of A systematic review of strategies used for controlling consumer moral hazard in health systems

Zohreh Koohi Rostamkalaee, Mehdi Jafari & Hasan Abolghasem Gorji
Supplementary Material 3

Additional file 1 of Barriers to physical activity in pregnant women living in Iran and its predictors: a cross sectional study

Zari Dolatabadi, Leila Amiri-Farahani, Katayon Ahmadi & Sally Pezaro
Additional file 1.

Additional file 2 of Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity

Nasrin Nassiri Koopaei, Mehrasa Shademani, Nasrin Shirzad Yazdi, Raheleh Tahmasvand, Mina Dehbid, Mansur Nassiri Koopaei, Homa Azizian, Zahra Mousavi, Ali Almasirad & Mona Salimi
Additional file 2: Table S1. Cytotoxicity screening (%) for compounds 4a–4i following treatment at 10 μM for 72 h, towards human cancer cell lines. Table S2. IC50 values for cytotoxic activity of doxorubicin towards cancer cells at 72 h.

Additional file 4 of The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019

Hamidreza Feizi, Mahasti Alizadeh, Seyed Aria Nejadghaderi, Maryam Noori, Mark J. M. Sullman, Javad Ahmadian Heris, Ali-Asghar Kolahi, Gary S. Collins & Saeid Safiri
Additional file 4: Table S4. DALYs due to chronic obstructive pulmonary disease in 1990 and 2019 for both sexes and percentage change in age-standardised rates (ASRs) per 100,000 in the Middle East and North Africa region (generated from data available from http://ghdx.healthdata.org/gbd-results-tool ).

Additional file 1 of Psychometric properties of public trust in Covid-19 control and prevention policies questionnaire

Riaz Alaei Kalajahi, Mohammad Saadati, Saber Azami Aghdash, Ramin Rezapour, Mehdi Nouri, Naser Derakhshani & Koustuv Dalal
Supplementary Material 1

Registration Year

  • 2023
    4
  • 2022
    48

Resource Types

  • Text
    52

Affiliations

  • Iran University of Medical Sciences
    52
  • Tehran University of Medical Sciences
    36
  • Tabriz University of Medical Sciences
    24
  • Universal Scientific Education and Research Network
    20
  • Shahid Beheshti University of Medical Sciences
    18
  • University of Nicosia
    18
  • NIHR Oxford Musculoskeletal Biomedical Research Centre
    16
  • Oxford University Hospitals NHS Trust
    16
  • University of Oxford
    16
  • Pasteur Institute of Iran
    6